Kazia Therapeutics Shares Fall After Pricing $40 Million Public Offering

Shares of Kazia Therapeutics Ltd (NASDAQ:KZIA) fell sharply in premarket trading Friday after the biotechnology company announced the pricing of a public offering expected to raise approximately $40 million in gross proceeds. The company's American Depositary Shares (ADSs) dropped 6.2% following the news.

Offering Details

Kazia Therapeutics announced it will sell 2,580,000 ADSs, each representing 500 of the company's ordinary shares, at a price of $15.50 per ADS. The offering is expected to close on or about August 31, 2026, subject to customary closing conditions.

Such capital raises can exert downward pressure on a company's stock price as the issuance of new shares can have a dilutive effect on the value of existing shares. The funds are intended to support the clinical development of paxalisib, Kazia's lead asset for treating various forms of cancer, as well as for working capital.

Warrants and Future Funding

Ad

The offering also includes two series of warrants, which, if exercised in full, could provide the company with an additional $80 million in gross proceeds before expenses. The specifics are as follows:

• Series A Warrants: To purchase up to 2,243,478 ADSs at an exercise price of $17.825 per ADS. These expire upon the earlier of 30 days after the company's Stage IV triple-negative breast cancer data readout (expected H2 2027) or five years from issuance.
• Series B Warrants: To purchase up to 2,064,000 ADSs at an exercise price of $19.375 per ADS. These expire upon the earlier of 30 days after the company's HR+/HER2- data readout (expected H1 2028) or five years from issuance.

Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering, according to the company's statement. BTIG and Needham & Company are serving as lead managers.